gemcitabine

P1, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> Jan 2027

P3, N=223, Terminated, Hoffmann-La Roche | Completed --> Terminated; Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).

P1, N=19, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed

P2, N=10, Recruiting, Hospital Universitario Dr. Jose E. Gonzalez

P3, N=88, Completed, Cairo University

P3, N=757, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting

P1, N=750, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting

This study reports AGP regimen as a promising therapeutic modality for PDAC, and provides a detailed mechanism by which a STING-mediated signaling relay from PDAC tumor cells to TAMs boost antitumor immunity and contribute to AGP chemotherapy efficacy. Furthermore, STING expression in tumor tissues correlated with improved prognosis, highlighting its potential as a predictive biomarker and promising therapeutic target.

Retrospective data indicate that gemcitabine plus platinum-based chemotherapy achieves the most consistent efficacy among conventional regimens, with median overall survival (OS) of 10-16 months...For clinical settings where comprehensive genomic profiling is not feasible, we discuss a pragmatic surrogate-based approach using imaging characteristics and serum tumor markers to guide initial treatment selection. We also address post-progression treatment considerations, including phenotype-based regimen switching and the role of re-biopsy.

Consequently, HA-PGC nanoparticles effectively convert cold tumors into hot tumors, significantly improving anti-PD-L1 immunotherapy efficacy. We demonstrated a novel, multifunctional nanoparticle platform combining chemodynamic therapy and immunotherapy, presenting a promising strategy to overcome resistance in triple-negative breast cancer treatment and guide future intelligent immunotherapeutic system design.

P3, N=999, Recruiting, Akeso | Not yet recruiting --> Recruiting

This study highlights that LDGC remodels the immunosuppressive microenvironment and potentiates anti-PD-L1 therapy, providing a rational regimen for ICC.